Navigation Links
Morcellator Lawsuit News: Bernstein Liebhard LLP Notes Financial Ties Between FDA Advisory Panel Members and Manufacturers of Power Morcellators

New York, NY (PRWEB) July 11, 2014

As part of its morcellator lawsuit ( investigation, Bernstein Liebhard LLP has been closely monitoring the ongoing meeting of the U.S. Food & Drug Administration’s (FDA) Obstetrics and Gynecology Devices Panel, which has been convened to explore ways to mitigate the cancer risks associated with the use of power morcellators in minimally invasive gynecological surgeries. According to a report published by Dow Jones Business News, a number of panel members have financial relationships with medical device companies that market power morcellators. One of those individuals, Dr. Andrew Brill, removed himself from the Panel two days before the meeting began, after the FDA reviewed more than $100,000 in fees he received from Johnson & Johnson’s Ethicon, Inc. unit. At least two other gynecologists on the panel have also had financial relationships with manufacturers, according to the report.*

“This Panel will make recommendations that could have financial consequences for companies that market power morcellators. It is important to avoid even the appearance of conflicts-of-interest among its members,” says Bernstein Liebhard LLP, a nationwide law firm representing victims of defective drugs and medical devices. The Firm is now evaluating morcellator lawsuits on behalf of women who may have experienced the upstaging of uterine sarcoma and other cancers due to uterine morcellation.

Morcellator Cancer Dangers
Power morcellators are used during laparoscopic hysterectomy and fibroid removals to shred tissue in order to facilitate its removal through a small abdominal incision. The FDA meeting, which continues today in Silver Spring, Maryland, is part of the agency’s ongoing review of cancer risks associated with the devices. In April, the FDA issued an alert discouraging doctors from using the devices in minimally invasive gynecological surgeries due to the potential that they can disseminate undetected uterine cancer cells into the peritoneal cavity. According to the agency, about 1 in 350 women undergoing fibroid removal has undetected cancer cells in their fibroids, and dissemination of these cells via morcellation can greatly reduce a patient’s odds of long-term survival.

Following the issuance of the FDA alert, Ethicon announced it would suspend sales of its Gynecare Morcellex,Morcellex Sigma Tissue Morcellator System, and Gynecare X-Tract Tissue Morcellator products pending further guidance from the agency.* A number of hospitals, including the Cleveland Clinic, have also moved to ban or limit the technique until the FDA completes its review.**

Victims of uterine cancer that was allegedly spread via a power morcellator may be eligible for compensation. To learn more about filing a morcellator lawsuit, please visit Bernstein Liebhard LLP's website. Free case reviews can also be obtained by calling 800-511-5092.

*, Dow Jones News Service, July 10, 2014
**, Reuters, April 30, 2014
***, Cleveland Plain Dealer, April 28, 2014

About Bernstein Liebhard LLP
Bernstein Liebhard LLP is a New York-based law firm exclusively representing injured persons in complex individual and class action lawsuits nationwide since 1993. As a national law firm, Bernstein Liebhard LLP possesses all of the legal and financial resources required to successfully challenge billion dollar pharmaceutical and medical device companies. As a result, our attorneys and legal staff have been able to recover more than $3 billion on behalf of our clients. The Firm has been named by The National Law Journal to the Plaintiffs Hot List, recognizing the top plaintiffs firms in the country, for the past 12 consecutive years. Bernstein Liebhard LLP is the only firm in the country to be named to this prestigious list every year since it was first published in 2003.

Bernstein Liebhard LLP
10 East 40th Street
New York, New York 10016

ATTORNEY ADVERTISING. © 2014 Bernstein Liebhard LLP. The law firm responsible for this advertisement is Bernstein Liebhard LLP, 10 East 40th Street, New York, New York 10016, 800-511-5092. Prior results do not guarantee or predict a similar outcome with respect to any future matter.
Contact Information:

Felecia L. Stern, Esq.
Bernstein Liebhard LLP

Read the full story at

Source: PRWeb
Copyright©2014 Vocus, Inc.
All rights reserved

Related medicine news :

1. Couple Sues Over Alleged Cancer Risk Associated with use of a Power Morcellator During the Woman's Laparoscopic Fibroid Removal Procedure, Parker Waichman Comments
2. GranuFlo Lawsuits News: Missouri Federal Court Returns Multi-Plaintiff Case to State Court, Rottenstein Law Group LLP Reports
3. Transvaginal Mesh Lawsuits Move Forward, as Bernstein Liebhard LLP Notes Issuance of New Order in Federal C.R. Bard Litigation
4. Lipitor Lawsuit News: Pfizer, Inc. Named in Whistleblower Lawsuit Alleging Improper Marketing of Lipitor, Bernstein Liebhard LLP Reports
5. Best Transvaginal Mesh Attorneys? Now Accepting Surgical Mesh Failure Victim Inquiries
6. DePuy ASR Lawsuit News: Bernstein Liebhard LLP Notes Upcoming Conference in New Jersey DePuy ASR Recall Litigation
7. Pradaxa Lawsuits Move Forward, as Federal Litigation Schedules January Status Conference, Bernstein Liebhard LLP Reports
8. Fosamax Lawsuits: Bellwether Trials Scheduled in Federal, State Fosamax Femur Fracture Litigations, Bernstein Liebhard LLP Reports
9. Class Action Lawsuit Filed on Behalf of West Virginia Residents Affected by Recent Chemical Spill
10. West Virginia Business Owners Represented in Class Action Lawsuit over Elk River Chemical Spill
11. Transvaginal Mesh Lawsuit News: Bellwether Trial in Federal C.R. Bard Vaginal Mesh Litigation Postponed, Bernstein Liebhard LLP Reports
Post Your Comments:
(Date:6/26/2016)... (PRWEB) , ... June 26, 2016 , ... Pixel Film ... Pro X. , "Film editors can give their videos a whole new perspective by ... Austin - CEO of Pixel Film Studios. , ProSlice Levels contains over 30 ...
(Date:6/26/2016)... ... June 26, 2016 , ... Many ... been diagnosed with endometriosis. These women need a treatment plan to not only ... approach that can help for preservation of fertility and ultimately achieving a pregnancy. ...
(Date:6/25/2016)... ... ... Bruton Memorial Library on June 21 due to a possible lice infestation, as reported by ... lice: the parasite’s ability to live away from a human host, and to infest common ... the event that lice have simply gotten out of control. , As lice are a ...
(Date:6/25/2016)... Beach, CA (PRWEB) , ... June 25, 2016 , ... ... UCLA with Magna Cum Laude and his M.D from the David Geffen School of ... Diego and returned to Los Angeles to complete his fellowship in hematology/oncology at the ...
(Date:6/25/2016)... ... June 25, 2016 , ... Conventional wisdom preaches the benefits of moderation, whether ... latter, setting the bar too high can result in disappointment, perhaps even self-loathing. However, ... their goal. , Research from reveals that behind the tendency ...
Breaking Medicine News(10 mins):
(Date:6/24/2016)... 24, 2016  Global Blood Therapeutics, Inc. (GBT) (NASDAQ: ... novel therapeutics for the treatment of grievous blood-based ... closing of its previously announced underwritten public offering ... public offering price of $18.75 per share. All ... by GBT. GBT estimates net proceeds from the ...
(Date:6/24/2016)... 2016 The Academy of Managed Care Pharmacy ... that would allow biopharmaceutical companies to more easily share ... formulary and coverage decisions, a move that addresses the ... The recommendations address restrictions in the sharing ... drug label, a prohibition that hinders decision makers from ...
(Date:6/24/2016)... According to a new market ... Needles, Safety Pen Needles), Needle Length (4mm, 5mm, 6mm, ... of Purchase (Retail, Non-Retail) - Trends & Global Forecasts ... market for the forecast period of 2016 to 2021. ... by 2021 from USD 1.65 Billion in 2016, growing ...
Breaking Medicine Technology: